Developing better and safer RNA drugs.

Abzu is a biotechnology company that applies AI to develop best-in-class RNA therapies for major medical needs.

Proven team, technology, and results.

We don't discover siRNA's, we program them.

Abzu combines deep RNA biology, AI-driven design, and drug development experience into a single execution engine.

We have designed and validated large numbers of siRNAs, ASOs, and anti-miRs across multiple partnered programs.
This work built the data, models, and experimental framework we now use to develop our own therapeutic pipeline.

Our AI-guided design platform allows us to explore and prioritise vast sequence space in silico.
We routinely evaluate 100,000+ design variants and predict efficacy and key developability properties before entering the lab.
This reduces experimental cycles, lowers cost, and shortens time to candidate selection.

The team brings hands-on experience across the full RNA drug development workflow, from computational design and delivery optimisation to preclinical strategy.

We have also applied our modelling approach to delivery, including structure–activity relationships for endosomal escape in next-generation LNP systems.

Together, this creates a closed learning loop where data improves models, and models improve molecules.

Using RNA to deliver RNA.

Extrahepatic delivery remains the central challenge for RNA therapeutics.

Our approach is to use RNA as the delivery vehicle.

We develop targeted aptamers that act as programmable carriers, enabling cell-specific uptake of therapeutic RNA.

This strategy is powered by the same design–build–test–learn framework that we use for drug discovery, allowing rapid optimisation of both targeting and payload.

The result is a modular platform for precision delivery beyond the liver.